• Biomolecules & Therapeutics
• /
• 제2권4호
• /
• pp.322-325
• /
• 1994

To optimize the immunological efficacy of CFC-101, an outer-membrane protein vaccine purified from relatively less pathogenic 4 different Pseudomonas aeruginosa strains, we investigated to establish its dose, administration route, interval and frequency of vaccination in mice. As expected, the 4 CFC-101 producing strains were less pathogenic than the challenging organism, P. aeruginosa GN11189. CFC-101 completely protected the death caused by P. aeruginosa at above 0.05 mg/kg vaccinized by 3 times with 7-day intervals. At the optimally effective dose of 0.2 mg/kg of CFC-101, at least 3 immunizations were necessary for complete protection against P. aeruginosa-induced death. If immunized 3 times, the immunization interval could be shortened up to 2 days to acquire the best protection against P. aeruginosa. CFC-101 was effective either by intraperitoneal, subcutaneous or intramuscular but not by oral administration. The present results show that the newly developed Pseudomonas vaccine, CFC-101, is highly effective for the protection from death caused by pseudomonal infections.

• Journal of Microbiology and Biotechnology
• /
• 제7권2호
• /
• pp.144-150
• /
• 1997

We developed a simple and efficient method to prepare a Pseudomonas vaccine of outer membrane (OM) proteins free from lipopolysaccharide (LPS). A three step purification process including extraction, ultrafiltration and ultracentrifugation effectively removed LPS from the OM protein fraction. Approximately 2 mg of the OM proteins was obtained from 1 g of wet cell. LPS contaminant in the vaccine preparation was less than 0.003% (w/w) of protein and protease activity was not detectable. To achieve a wide range of protection, OM proteins prepared from four attenuated P. aeruginosa strains were mixed in equal amounts and used as a vaccine, which elicited in rabbits a high titer of antibody reactive to all of the seven Fisher types. The antisera from the immunized rabbit had a strong reactivity to vaccine proteins larger than 25 kDa. In a burned mouse infection model, immunization with the vaccine significantly enhanced bacterial clearance in the Pseudomonas infected skin. The vaccination also provided mice an excellent protection against Pseudomonas infection (11, 16). Data on antigenicity, mutagenicity, acute, subacute toxicity and pharmacological tests confirmed the safety of the vaccine (1, 3, 10, 12, 17). These data demonstrate that this method can be applied to manufacture a bacterial vaccine of OM proteins with safety and prophylactic efficacy at a practical low cost.

• Biomolecules & Therapeutics
• /
• 제2권4호
• /
• pp.326-330
• /
• 1994

The treatment of pseudomonal infection is a perplexed problem because of its modest susceptibility to most of the major antibiotics. A novel Pseudomonas vaccine(CFC-101) was prepared from the outer membrane protein fractions of several Pseudomonas strains. In this study, we examined CFC-101's effectiveness in both active and passive immunization models. CFC-101 in mice at 0.2 mg/kg, i.p., given three times at two-day intervals, completely prevented the death caused by Pseudomonas aeruginosa. Antibody titer, in accordance with the protective effect in this active immunization, was elevated to its peak level following three consecutive administrations of CFC-101. Thereafter, antibody titer stayed at a constantly high level. Each outer membrane protein fraction from the four CFC-101 producers, exhibited good cross-protective effects in mouse infection models against different Fisher types of P. aeruginosa. In the passive immunization model, 21~336 $\mu\textrm{g}$/kg of anti-rabbit IgG to CFC-101, when mice being infected with a challenge strain, prevented the Pseudomonhas-induced death up to 60%. Therefore, the preventive effect of CFC-101 was verified in both the active and passive immunization models.

• Biomolecules & Therapeutics
• /
• 제2권4호
• /
• pp.331-335
• /
• 1994

As a part of the safety evaluation of Pseudomonas vaccine(CFC-101), antigenicity tests were carried out in guinea pigs and mice. In active systemic anaphylaxis(ASA) test, guinea pigs showed no sign or only moderate sign(1/5) when sensitized and challenged with up to 200 $\mu\textrm{g}$/kg. In homologous passive cutaneous anaphylaxis(PCA) test using guinea pigs, inoculation of CFC-101 alone did not produce CFC-101-specific antibody. When inoculated with 200 $\mu\textrm{g}$/kg plus adjuvant, challenge of 200 $\mu\textrm{g}$/kg produced PCA titer of 32(5/5) but challenge of 20 $\mu\textrm{g}$/kg did not produce CFC-101-specific antibody. In heterologous PCA test using mice, CFC-101-specific antibody was not detected when sensitized with CFC-101 alone. Some animals(3/12) showed positive PCA response when inoculated with 200 $\mu\textrm{g}$/kg plus alum. In passive hemagglutination (PHA) test, although no antibody was detected at 20 $\mu\textrm{g}$/kg, inoculation of 200 $\mu\textrm{g}$/kg alone or with alum produced positive response in all animals. This result has already been predicted because CFC-101 is a vaccine developed for the purpose of immunization. From the above results, it can be concluded that there is no adverse antigenic potential up to 10 times clinical dose of 200 $\mu\textrm{g}$/kg.

• Journal of Microbiology and Biotechnology
• /
• 제27권8호
• /
• pp.1539-1548
• /
• 2017

Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly causes fatal infections in cystic fibrosis and burn patients as well as in patients who are hospitalized or have impaired immune systems. P. aeruginosa infections are difficult to treat owing to the high resistance of the pathogen to conventional antibiotics. Despite several efforts, no effective prophylactic vaccines against P. aeruginosa are currently available. In this study, we investigated the activity of the CIA06 adjuvant system, which is composed of alum and de-O-acylated lipooligosaccharide, on a P. aeruginosa outer membrane protein (OMP) antigen vaccine in mice. The results indicated that CIA06 significantly increased the antigen-specific IgG titers and opsonophagocytic activity of immune sera against P. aeruginosa. In addition, the antibodies induced by the CIA06-adjuvanted vaccine exhibited higher cross-reactivity with heterologous P. aeruginosa strains. Finally, mice immunized with the CIA06-adjuvanted vaccine were effectively protected from lethal P. aeruginosa challenge. Based on these data, we suggest that the CIA06 adjuvant system might be used to promote the immunogenicity and protective efficacy of the P. aeruginosa OMP vaccine.

• Pediatric Infection and Vaccine
• /
• 제13권2호
• /
• pp.180-185
• /
• 2006

침습적 Pseudomonas 감염은 대개 면역 저하 환자들에서 발생하며, 이는 높은 사망률과 관련이 있다. 그러나 드물게는 면역력이 정상인 숙주에서도 발생할 수 있다. 첫 번째 증례는 괴저성 농창과 Pseudomonas 패혈증이 발생한 5개월 여아이며, 두번째 증례는 9개월 남아에서 지역사회 감염으로 발생한 폐렴과 Pseudomonas 패혈증이다. 두 환아 모두에서 녹농균이 배양검사로 증명되어 감수성 있는 항생제를 사용하였으며, T 림프구, B 림프구, 보체, 식세포 등 면역력에 대한 검사는 모두 정상이었다. 저자들은 이전에 건강했던 영아들에서 발생한 침습성 녹농균 감염증 2례를 경험하였기에 이를 보고하는 바이다.

• Parasites, Hosts and Diseases
• /
• 제58권2호
• /
• pp.173-179
• /
• 2020

Leishmaniasis is a prevalent cause of death and animal morbidity in underdeveloped countries of endemic area. However, there is few vaccine and effective drugs. Antimicrobial peptides are involved in the innate immune response in many organisms and are being developed as novel drugs against parasitic infections. In the present study, we synthesized a 5-amino acid peptide REDLK, which mutated the C-terminus of Pseudomonas exotoxin, to identify its effect on the Leishmania tarentolae. Promastigotes were incubated with different concentration of REDLK peptide, and the viability of parasite was assessed using MTT and Trypan blue dye. Morphologic damage of Leishmania was analyzed by light and electron microscopy. Cellular apoptosis was observed using the annexin V-FITC/PI apoptosis detection kit, mitochondrial membrane potential assay kit and flow cytometry. Our results showed that Leishmania tarentolae was susceptible to REDLK in a dose-dependent manner, disrupt the surface membrane integrity and caused parasite apoptosis. In our study, we demonstrated the leishmanicidal activity of an antimicrobial peptide REDLK from Pseudomonas aeruginosa against Leishmania tarentolae in vitro and present a foundation for further research of anti-leishmanial drugs.

• Pediatric Infection and Vaccine
• /
• 제30권1호
• /
• pp.47-54
• /
• 2023

최근 광범위 항생제 사용의 증가로 인한 다제내성 그람 음성균의 출현이 전 세계적으로 문제가 되고 있다. 특히 다제내성 녹농균(multidrug-resistant Pseudomonas aeruginosa) 감염의 치료는 어려우며 중환자의 사망률을 증가시키는 원인이 된다. 세프톨로잔-타조박탐(ceftolozane-tazobactam, Zerbaxa^TM)은 5세대 세팔로스포린과 베타락탐 분해효소저해제로 다제내성 녹농균에 의한 복잡성 요로감염과 복잡성 복강내 감염의 치료에 효과가 있는 것으로 입증되었다. 본지에서 저자들은 소아청소년 혈액암 환자에서 발생한 다제내성 녹농균에 의한 균혈증을 세프톨로잔-타조박탐을 사용하여 성공적으로 치료한 국내 첫 번째 사례를 보고하고자 한다.

• Pediatric Infection and Vaccine
• /
• 제9권1호
• /
• pp.104-109
• /
• 2002

녹농균은 면역질환이 있거나, 기저의 악성질환이 있을 때 주로 감염되며, 건강한 환아에서 감염되는 경우는 흔하지 않다. 저자들은 특별한 면역질환이나 기저질환 없이 녹농균감염이 간, 신장, 피부 등에 다발적으로 발생하여 간농양과 신농양, 신우신염을 동반한 괴저성 농창으로 진단된 1례를 경험하였기에 보고하는 바이다. 괴저성 농창은 조기 진단과 조기 치료가 예후에 중요한데, 본 증례에서는 비교적 조기 진단과 치료가 이루어져 좋은 예후를 보인 것으로 사료된다.

• Pediatric Infection and Vaccine
• /
• 제25권1호
• /
• pp.1-7
• /
• 2018

목적: 본 연구에서는 천공성 충수염을 예측할 수 있는 인자들을 분석하고, 원인균을 조사하고자 하였다. 방법: 2012년 1월부터 2014년 12월까지 한림대학교 성심병원에서 19세 미만에 충수염으로 수술을 진행한 569명을 대상으로 하였다. 이들의 입원 당시의 병력청취 기록과 혈액검사, 영상검사, 균 배양검사를 분석하였다. 결과: 총 569명 중 127명(22%)에서 천공이 확인되었다. 충수염의 천공 비율은 소아기, 학령기, 청소년기에서 각각 50%, 27.8%, 16.8%였다. 높은 C-반응단백질 수치, 충수대변돌 존재가 천공 충수염의 위험인자였다(P<0.001). 24명의 환자에서, 수술 중 복강 내 복막액 또는 충수 주위에 농이 관찰될 때 균 배양검사를 시행하였고, 16명(66%)에서 균이 배양되었다. 가장 많이 배양된 균은 Escherichia coli(n=10)였다. 나머지 균은 Pseudomonas aeruginosa, Streptococcus spp., Staphylococcus spp.였다. 결론: 5세 이하의 환자에서 충수염의 천공 비율은 50%였고, 천공 비율은 나이가 많을수록 낮았다. 충수염 진단 당시 C-반응단백질 수치가 높거나, 영상검사에서 충수대변돌이 관찰될 때, 천공성 충수염 가능성이 높으므로 주의해야 한다.